Amgen Inc. (AMGN)

FairStock Score: 54/100 — MIXED

Key Financials

Strengths

• Dominant market position in biopharmaceuticals with multiple blockbuster drugs generating $9.9B quarterly revenue
• Exceptional free cash flow generation of $7.5B annually providing financial flexibility and shareholder returns
• Remarkable 106% ROE demonstrating efficient capital deployment despite high leverage
• Defensive business model with low beta of 0.42 and essential therapeutic products with sticky customer bases
• Strong net margin of 13.51% in latest quarter showing pricing power and operational efficiency

Concerns

• Severe overvaluation with Graham Number of $29.88 versus market price of $369.53, indicating massive bubble risk
• Dangerously high leverage with D/E ratio of 6.40 and Altman Z-Score of 1.33 suggesting financial fragility
• Disappointing ROCE of 7.93% below typical cost of capital, indicating value destruction despite high returns
• Deteriorating financial quality with Piotroski F-Score of only 6/9 and missing growth data suggesting deceleration

AI Analysis

Amgen presents a classic case of a quality business trading at a premium valuation that demands scrutiny. The company operates in healthcare with established franchises like Enbrel, Prolia, and Repatha—genuine competitive moats backed by patent protection and switching costs. A 106% ROE and $7.5B annual free cash flow demonstrate operational excellence. However, I'm troubled by the valuation disconnect. At $369.53 with a Graham Number of merely $29.88, we're looking at a -1137% margin of safety. The P/E of 24.44 alongside an EV/EBITDA of 74.17 suggests the market has priced in perfection. My concerns deepen examining the balance sheet: a D/E ratio of 6.40 is aggressive for a pharmaceutical company, and the Altman Z-Score of 1.33 sits dangerously in distress territory. The Piotroski F-Score of 6/9 indicates deteriorating financial quality. While the company generates genuine cash—evidenced by modest FCF yield of 0.5%—the low ROCE of 7.93% relative to cost of capital is disappointing. Growth metrics show N/A figures, suggesting deceleration. Amgen is a wonderful business at the wrong price. I'd much rather own this at $150 than at $369. The dividend yield being N/A raises questions about capital allocation priorities. For long-term compounders, I seek quality at reasonable prices; Amgen fails this test today.

Bull Case

Amgen's diversified pipeline could unlock significant value as newer therapies gain market penetration, particularly in oncology and cardiovascular disease. The company's unmatched scale, manufacturing capabilities, and distribution network create durable competitive advantages that justify premium valuations in a consolidating biotech landscape.

Bear Case

Patent expirations on key franchises combined with biosimilar competition will pressure cash flows and margins significantly over the next 5-7 years. The current valuation leaves zero margin of safety, and deteriorating financial metrics suggest management may struggle to service the 6.4x debt load if growth disappoints.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer